Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas.
Interius BioTherapeutics has raised $51.4M in total funding. The most recent round was Series B. The last funding was announced in June 2024.
Interius BioTherapeutics's investors include RA Capital Management, Cormorant Asset Management, Longwood Fund, Agent Capital, University of Pennsylvania.
Interius BioTherapeutics is headquartered in Philadelphia, United States.
Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas.
Interius BioTherapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Interius BioTherapeutics — Funding & Investors." VCBacked, June 3, 2024, https://www.vcbacked.co/company/interius-biotherapeutics. Accessed July 19, 2026.
VCBacked. (2024). Interius BioTherapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/interius-biotherapeutics
{{cite web |title=Interius BioTherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/interius-biotherapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated